Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The present application relates to a balloon catheter, which is a rapid exchange structure and has a balloon catheter body and a hub, wherein the balloon catheter body has a push member, a transition member, a balloon loading member, a balloon, a imaging mark and a tip head, the balloon loading member comprises an outer tube and an inner tube, a distal end of the handle is connected with a proximal end of the push member, a proximal end of the transition member extends from a distal end of the push member, a distal end of the transition member is nested inside a proximal end of the outer tube of the balloon loading member, the balloon loading member loads the balloon, the tip head is provided on a distal end of the balloon, the imaging mark is provided on the balloon loading member, characterized in that the balloon has a wall thickness of 10-15 microns, the balloon has a nominal dilation pressure of 3-4 atm, and the balloon catheter has a rated burst pressure of is 10-12 atm.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipateldisappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The present invention provides a transapical implantable mitral valve device, which includes an outer valve stent comprising an outer valve stent body that is composed of a plurality of first structure units arranged in the circumferential direction and an anchoring unit that is disposed on the outer valve stent body for anchoring the mitral valve device in a human body, at least one of an inner surface and an outer surface of the outer valve stent body being covered with an outer skirt; an inner valve stent disposed inside the outer valve stent and interconnected with the outer valve stent, a cavity being formed between the outer valve stent and the inner valve stent; and a valve leaflet structure disposed in the inner valve stent to form a prosthetic valve.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The present application relates to a balloon catheter, which is a rapid exchange structure and has a balloon catheter body and a hub, wherein the balloon catheter body has a push member, a transition member, a balloon loading member, a balloon, a imaging mark and a tip head, the balloon loading member comprises an outer tube and an inner tube, a distal end of the handle is connected with a proximal end of the push member, a proximal end of the transition member extends from a distal end of the push member, a distal end of the transition member is nested inside a proximal end of the outer tube of the balloon loading member, the balloon loading member loads the balloon, the tip head is provided on a distal end of the balloon, the imaging mark is provided on the balloon loading member, characterized in that the balloon has a wall thickness of 10-15 microns, the balloon has a nominal dilation pressure of 3-4 atm, and the balloon catheter has a rated burst pressure of is 10-12 atm.

Abstract: The invention relates to an apparatus for breaking thrombus and aspirating the thrombus comprising: an aspirating rotary grinding hand-held system which integrates a rotary grinding head driving device, an aspirating device, a power supply device and a control device; a micro catheter device which is communicated with the aspirating device and the rotary grinding head driving device, respectively; a waste liquid collecting device which is connected to the aspirating device, wherein the aspirating device and the waste liquid collecting device form an airtight passage; and a distal end rotary grinding head device which is connected to the rotary grinding head driving device through a connection mandrel, wherein the power supply device provides power for the rotary grinding head driving device; wherein the distal end rotary grinding head device and the connection mandrel are accommodated in an inner cavity of the micro catheter device; and wherein the control device controls the aspirating device and the rotary

Abstract: Medical devices and methods for endovascularly or transcatheterly replacing a patient's heart valve, including: a delivery system (9) having an entry profile of 30 Fr or less; a self-expandable annulus ring (10) disposed in the delivery system (9) including a self-expandable anchoring and clipping structure and multiple bridges (4) connected to the anchoring and clipping structure; and a replacement heart valve (11) disposed in the delivery system (9) and connected to the bridges (4). The bridges (4) are formed of a shape memory material; during deployment, the bridges (4) fold upwardly inside the self-expandable anchoring and clipping structure to lift the replacement heart valve (11) into position.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a valve body defining a ventricular end of the device, and an annulus support that connects the atrial flange and the valve body, the annulus support including a ring of tabs extending radially therefrom and adapted to engage the native mitral annulus and/or the native leaflet(s) of the human heart. The atrial flange can be seated in the atrium above the native mitral valve annulus in a human heart, and the ring of tabs can engage the native mitral annulus in a manner where the atrial flange and tabs provide a clipping effect to secure the mitral valve replacement device at the native mitral valve position.